Catalyst Wire Dossier Catalyst Wire Dossier

MK-3102

· Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MK-3102, covering 2015-10-29 to 2015-11-25. Get the full timeline:

Most recent: Clinical Trial Update: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) [Phase 3]

See pricing